Erectile Dysfunction Clinical Trial
Official title:
Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.
The aim of this study is to determine if patients with ED taking PDE5 inhibitors (e.g. Viagra, CIalis, Levitra, Stendra) and experiencing performance anxiety will benefit using a user-friendly stress reducing phone app, Serenita. The study is internet based with no office visits.
The etiology of erectile dysfunction (ED) has been investigated in many studies. Most often,
ED is proposed to have a multifactorial etiology, with organic and/or psychogenic causal
factors hypothesized to affect erectile function. Numerous studies show that Deep and Slow
Breathing (DSB) reduces stress and anxiety.
Since ED is multifactorial, many physicians rely solely on phosphodiesterase-5 (PDE-5)
inhibitors to increase blood flow to the arteries to maintain an erection. Although it works
in many patients, some patients can get overly anxious prior to sexual intercourse and not
be able to produce or maintain an erection. While some patients may realize that DSB may
improve their anxiety they don't know how to perform DSB properly. We hypothesize that by
providing software interactivity on deep and slow breathing to this group of ED patients,
may in turn help reduce their anxiety, thus, maximize the effect of PDE5 inhibitors. The app
called "Serenita" for mobile phones, designed by Eco-Fusion will be utilized in this study.
The app performs two functions: it detects stress and focus level and It guides the user
through a personalized breathing exercise designed to reduce stress and increase focus.
Breathing as a method to treat stress has three scientifically validated variations, the
deep diaphragmatic breathing, used for centuries as part of Yoga which often refers as Yogic
breathing, biofeedback breathing, a method in which the user sees in real-time how his
breathing affects his stress level, and coherence breathing, a method that synchronizes
breathing pace with heart rhythms. The technology embedded in Serenita app combines all
three methods into a personalized guided breathing regimen. The app acquires data by turning
the mobile phone's camera into a biomedical sensor which peers into a person's blood stream,
obtaining heart rate, heart rate variability and breathing pace. Then the app processes the
data obtained to assess user's stress and focus level.
This study will utilize 6 standardized questionnaires to assess changes in patients'
responses while using the app:
- Erectile Performance Anxiety Index (EPAI), which will ask questions that assess anxiety
about being able to achieve or maintain an erection during sexual activity.
- International Index of Erectile Function (IIEF), which will ask questions about sexual
encounters for the past four weeks.
- Psychological and Interpersonal Relationship Scales (PAIRS), which will ask questions
about sexual self-confidence, time concerns and spontaneity with sexual encounters.
- Self-Esteem and Relationship (SEAR), which will ask questions about sexual
relationship, confidence, stress ad perceived stress and overall sexual relationship
for the past four weeks.
- Sexual Encounter Profile (SEP), which will ask question about each sexual attempt.
- Global Assessment Question, which will ask question at end of study if this app has
improved erectile function.
These questionnaires are conducted online for easy access and completion. There are no
office visits.
Registration to the study could be done at: http://eepurl.com/b3DcP1
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |